Abstract
Botulinum neurotoxin (BoNT) is the most potent biologic toxin known to a man (Gill 1982). Its clinical effects have been recognized since the end of the nineteenth century, when van Ermengem (1897) related botulism to a toxin produced by Clostridium botulinum, an anaerobic bacterium. The analysis of botulism outbreaks has led to the recognition that human intoxication may be caused by BoNT types A, B, E, and F (Green et al. 1983; Sakaguchi 1983). There are three other antigenically distinct toxins (C, D, and G) (Simpson 1981). These serotypes are produced by distinct strains of C. botulinum (Schantz and Johnson 1992). Although outbreaks of botulism have been identified as recently as in 1989 (Critchley et al. 1989), in the past two decades medical interest in BoNT has been fueled by the demonstration of its therapeutic usefulness. In 1973 Scott used BoNT type A for treatment of strabismus in nonhuman primates, and 8 years later he reported the results of his initial experience with this toxin to correct strabismus in humans (Scott 1981). Since then BoNT injections have been demonstrated to be a safe and efficient therapy for a large number of neurologic and nonneurologic diseases (Jankovic and Brin 1991). In December 1989 the United States Food and Drug Administration approved BoNT type A for the treatment of strabismus, blepharospasm, and hemifacial spasm in patients 12 years of age and older.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
American Academy of Ophthalmology (1989) Botulinum toxin therapy of eye muscle disorders: safety and effectiveness. Ophthalmology 96(2): 37–41
American Academy of Otolaryngology (1990) Position statement on the clinical usefulness of botulinum J toxin in the treatment of spasmodic dysphonia. Arch Otolaryngol Head Neck Surg Bull 9: 8
Aronson AE, De Santo LW (1983) Adductor spastic dysphonia: three years after recurrent laryngeal nerve section. Laryngoscope 93: 1–8
Avila OL, Drachman DB, Pestronk A (1989) Neurotransmission regulates stability of acetylcholine receptors at the neuromuscular junction. J Neurosci 9: 2902–2906
Benabid AL, Pollak P, Gervason C, Hoffman D, Gao DM, Hommel M, Perret SE, de Rougemont S (1991) Long-term suppression of tremor by chronic stimulation of the ventral intermediate thalamic nucleus. Lancet 337: 403–406
Bertrand CM, Molina-Negro P (1988) Selective peripheral denervation in 111 cases of spasmodic torticollis: rationale and results. Adv Neurol 50: 637–643
Biglan AW, Gonnering R, Lockhart LB, Rabin B, Fuerste FH (1986) Absence of antibody production in patients treated with botulinum A toxin. Am J Opthalmol 101: 232–235
Biglan AW, Bumstine RA, Rogers GL, Saunders RA (1989) Management of strabismus with botulinum toxin A. Opthalmology 96: 935–943
Black JD, Dolly JO (1987) Selective location of acceptors for botulinum neurotoxin A in the central and peripheral nervous systems. Neuroscience 23: 767–779
Blackie JD, Lees AJ (1990) Botulinum toxin treatment in spasmodic torticollis. J Neurol Neurosurg Psychiatry 53: 640–643
Blasi J, Chapman ER, Link E, Binz T, Yamasaki S, DeCamilli P, Südhof T, Niemann H, Jahn R (1993a) Botulinum neurotoxin A selectively cleaves the synaptic protein SNAP-25. Nature 365: 160–163
Blasi J, Chapman ER, Yamasaki S, Binz T, Niemann H, Jahn R (1993b) Botulinum neurotoxin C blocks neurotransmitter release by means of cleaving HPC-1/syntaxin. EMBO J 12: 4821–4828
Blitzer A, Brin MF (1991) Laryngeal dystonia: a series with botulinum toxin therapy. Ann Otol Rhinol Laryngol 100: 85–89
Blitzer A, Brin MF, Fahn S, Lovelace RE (1986) Botulinum toxin for the treatment of spastic dysphonia. Laryngoscope 96: 1300–1301
Blitzer A, Brin MF, Fahn S, Lovelace RE (1988a) Localized injections of botulinum toxin for the treatment of focal laryngeal dystonia (spastic dysphonia). Laryngoscope 98: 193–197
Blitzer A, Brin MF, Fahn S, Lovelace RE (1988b) Clinical and laboratory characteristics of focal laryngeal dystonia: study of 110 cases. Laryngoscope 98: 636–640
Blitzer A, Brin MF, Fahn S (1989) Botulinum toxin injection for the treatment of oromandibular dystonia. Ann Otol Rhinol Laryngol 98: 93–97
Blum P, Jankovic J (1991) Stiff-person syndrome: an autoimmune disease. Mov Disord 6: 12–20
Borodic GE (1994) Hemifacial spasm: evaluation and management, with emphasis on botulinum toxin therapy. In: Jankovic J, Hallet M (eds) Therapy with botulinum toxin. Dekker, New York, pp 331–351
Borodic GE, Joseph M, Fay L, Cozzolino D, Ferrante R (1990) Botulinum A toxin for the treatment of spasmodic torticollis: dysphagia and regional toxin spread. Head Neck 12: 392–398
Borodic GE, Cozzolino D, Ferrante R, Wegner AW, Young RR (1991a) Innervation zone of orbicularis oculi muscle and implications for botulinum A therapy. Ophthalmic Plast Reconstr Surg 7: 54–60
Borodic GE, Pearce LB, Johnson EA, Schantz EJ (1991b) Clinical and scientific aspects of botulinum A toxin. Ophthalmol Clin North Am 4: 491–503
Borodic GE, Pearce LB, Smith K, Joseph M (1992) Botulinum A toxin for spasmodic torticollis: multiple vs single injection points per muscle. Head Neck 14: 33–37
Borodic GE, Pearce LB, Cheney M, Metson R, Brownstone D, Townsed D, McKenna M (1993a) Botulinum A toxin for treatment of aberrant facial nerve regeneration. Plast Reconstr Surg 91: 1042–1045
Borodic GE, Pearce LB, Ferrante R (1993b) Therapeutic botulinum toxin: histologic effects and diffusion properties. In: DasGupta BR (ed) Botulinum and tetanus neurotoxins. Plenum, New York, pp 623–645
Borodic GE, Pearce LB, Smith KL et al (1993c) Botulinum B toxin as an alternative to botulinum A toxin: a histologic study. Ophthalmic Plast Reconstr Surg 9: 182–190
Borodic GE, Ferrante R, Pearce LB, Smith K (1994) Histologic assessment of dose-related diffusion and muscle fiber response after therapeutic botulinum A toxin injections. Mov Disord 9: 31–39
Brewer GJ, Yuzbasiyan-Gurkan V (1992) Wilson disease. Medicine 71: 139–164
Brin MF, Fahn S, Moskowitz C, Friedman A, Shale HH, Greene PE, Blitzer A, List T, Lange D, Lovelace RE, et al. (1987) Localized injections of botulinum toxin for the treatment of focal dystonia and hemifacial spasm. Mov Disord 2: 237–254
Brin MF, Blitzer A, Fahn S, Gould W, Lovelace RE (1989) Adductor laryngeal dystonia (spastic dysphonia): treatment with local injections of botulinum toxin (BOTOX). Mov Disord 4: 287–296
Brin MF, Blitzer AB, Stewart C, Fahn S (1990) Botulinum toxin: now for abductor laryngeal dystonia. Neurology 40 [Suppl 1]: 381
Brin MF, Blitzer A, Stewart C, Fahn S (1992a) Treatment of spasmodic dysphonia (laryngeal dystonia) with local injections of botulinum toxin: review and technical aspects. In: Blitzer A, Brin MF, Sasaki CT, Fahn S, Harris KS (eds) Neurologic disorders of the larynx. Thieme, Stuttgart, pp 214–228
Brin MF, Stewart C, Viswanath NS et al. (1992b) Pilot study: laryngeal botulinum toxin (Botox) injections for disabling stuttering in adults. Neurology 42 [Suppl 3]: 376
Cardoso F, Jankovic J (1995) Blepharospasm. In: Tsui JKC, Calne DB (eds) Handbook of dystonia. Dekker, New York, (in press)
Carruthers A, Carruthers JDA (1994) Botulinum toxin in the treatment of glabellar frown lines and other facial wrinkles. In: Jankovic J, Hallet M (eds) Therapy with botulinum toxin. Dekker, New York, pp 577–596
Chan J, Brin MF, Fahn S (1991) Idiopathic cervical dystonia: clinical characteristics. Mov Disord 6: 119–126
Clarke CE (1992) Therapeutic potential of botulinum toxin in neurological disorders. Q J Med 299: 197–205
Clarke JR, Spalton DJ (1988) Treatment of senile entropion with botulinum toxin. Br J Ophthalmol 72: 361–362
Cohen DA, Savino PJ, Stern MB, Hurtig Hl (1986) Botulinum injection therapy for blepharospasm: a review and report of 75 patients. Clin Neuropharmacol 9: 415–429
Cohen LG, Hallet M, Geller BD, Hochberg F (1989) Treatment of focal dystonias of the hand with botulinum toxin injections. J Neurol Neurosurg Psychiatry 52: 355–363
Cornelia CL, Buchman AS, Tanner CM, Brown-Toms NC, Goetz CG (1992a) Botulinum toxin injections for spasmodic torticollis: increased magnitude of benefit with electromyographic assistance. Neurology 42: 878–882
Cornelia CL, Tanner CM, DeFoor-Hill L, Smith C (1992b) Dysphagia after botulinum toxin injections for spasmodic torticollis: clinical and radiologic findings. Neurology 42: 1307–1307
Critchley EMR, Hayes PJ, Isaacs PET (1989) Outbreak of botulism in north west England and Wales. Lancet 2: 849–853
Das TK, Park DM (1989) Effect of treatment with botulinum toxin on spasticity. Postgrad Med J 65: 208–210
DasGupta BR (1989) The structure of botulinum neurotoxin. In: Simpson LL (ed) Botulinum neurotoxin and tetanus toxin. Academic San Diego pp 53–66
DasGupta BR (1994) Structures of botulinum neurotoxin, its functional domains, and perspectives on the crystalline type A toxin. In: Jankovic J, Hallett M (eds) Therapy with botulinum toxin. Dekker, New York, 15–40
Davis D, Jabbari B (1993) Significant improvement of stiff-person syndrome after paraspinal injection of botulinum toxin A. Mov Disord 8: 371–373
Dedo HH (1976) Recurrent laryngeal nerve section for spastic dysphonia. Ann Otol Rhinol Laryngol 85: 451–459
Deuschl G, Heinen F, Kleedorfer B, Wagner M, Lucking CH, Poewe UV et al (1992) Clinical and polymyographic investigation of spasmodic torticollis. J Neurol 239: 9–15
Dezfulian M, Bartlett JG (1984) Detection of Clostridium botulinum type A toxin toxin by enzyme-linked immunosorbent assay with antibodies produced in immunologically tolerant animals. J Clin Microbiol 19: 645–648
Dressier D, Schonle PW (1991) Hyperkinesias after hypoglossofacial nerve anastomosis—treatment with botulinum toxin. Eur Neurol 31: 44
Dubinsky RM, Gray CS, Vetere-Overfield B, Koller WC (1991) Electromyographic guidance of botulinum toxin treatment in cervical dystonia. Clin Neuropharmacol 14: 14: 262–267
Duchen LW (1970) Changes in motor innervation and Cholinesterase localization induced by botulinum toxin in skeletal muscle of the mouse: differences between fast and slow muscles. J Neurol Neurosurg Psychiatry 33: 40–54
Duchen LW (1972) Motor nerve growth induced by botulinum toxin as a regenerative phenomenon. Proc R Soc Med 65: 196–197
Dunn WJ, Arnold AC, O’Connor PS (1986) Botulinum toxin for the treatment of dysthyroid ocular myopathy. Ophthalmology 93: 470–475
Dutton JJ, Buckley EG (1988) Long-term results and complications of botulinum A toxin in the treatment of blepharospasm. Ophthalmology 95: 1529–1534
Dykstra DD (1994) Effects of botulinum A toxin on detrusor-sphincter dyssinergia in spinal cord injury patients. In: Jankovic J, Hallet M (eds) Therapy with botulinum toxin. Dekker, New York, pp 535–542
Dykstra DD, Sidi AA (1990) Treatment of detrusor-sphincter dyssinergia with botulinum A toxin: a double-blind study. Arch Phys Med Rehabil 71: 24–26
Dykstra DD, Sidi A, Scott AB, Pagel JM, Goldfish GD (1988) Effects of botulinum A toxin on detrusor-sphincter dyssenergia in spinal cord injury patients. J Urol 139: 912–922
Elston JS (1986) Botulinum toxin treatment of hemifacial spasm. J Neurol Neurosurg Psychiatry 49: 827–829
Elston J (1992) The management of blepharospasm and hemifacial spasm. J Neurol 239: 5–8
Elston JS (1994) Botulinum toxin for blepharospasm. In: Jankovic J, Hallet M (eds) Therapy with botulinum toxin. Dekker, New York pp 191–198
Erenberg G (1992) Treatment of Tourette syndrome with neuroleptic drugs. Adv Neurol 58: 241–243
Fitzsimons R, Lee J, Elston J (1989) The role of botulinum toxin in the management of sixth nerve palsy. Eye 3: 391–400
Ford CN, Bless DM, Lowery JD (1990) Indirect laryngoscopy approach for injection of botulinum toxin in spasmodic dysphonia. Otolaryngol Head Neck Surg 103: 752–758
Frueh BR, Nelson CC, Kapustiak JF, Musch DC (1988) The effect of omitting botulinum toxin from the lower eyelid in blepharospasm treatment. Am J Ophthalmol 106: 46–47
Gacek RR (1987) Botulinum toxin for relief of spasmodic dysphonia. Arch Otolaryngol Head Neck Surg 113: 1240
Gandras F, Elston J, Quinn N, Marsden CD (1988) Blepharoespasm: a review of 264 patients. J Neurol Neurosurg Psychiatry 51: 767–772
Garner CG, Straube A, Gasser T et al. (1990) Early-single-fibre-EMG findings in patients with therapeutic use of botulinum toxin distant to the site of treatment. Mov Disord 5: 76
Garner CG, Straube A, Witt TN, Gasser T, Oertel WH (1993) Time course of distant effects of local injections of botulinum toxin. Mov Disord 8: 33–37
Gelb DJ, Lowenstein DH, Aminoff MF (1989) Controlled trial of botulinum toxin injections in the treatment of spasmodic torticollis. Neurology 39: 80–84
Gill DM (1982) Bacterial toxins: a table of lethal amounts. Microbiol Rev 46: 86–94
Glanzman KL, Gelb DJ, Drury MB, Bromberg MB, Truong DD (1990) Brachial plexopathy after botulinum toxin injections. Neurology 40: 1143
Gonnering RS (1988) Negative antibody response to long-term treatment of facial spasms with botulinum toxin. Am J Ophthalmol 105: 313–315
Green J, Spear H, Brinson RR (1983) Human botulism (type F)—a rare type. Am J Med 75: 893–895
Greene PE, Fahn S (1993) Use of botulinum toxin type F to treat torticollis patients with immunity to botulinum toxin type A. Mov Disord 8: 479–483
Greene P, Fahn S, Diamond B (1994) Development of resistance to botulinum toxin type A in patients with tortivollis. Mov Disord 9: 213–217
Greene P, Shale H, Fahn S (1988) Analysis of open-labels trials in torsion dystonia using high dosages of anticholinergics and other drugs. Mov Disord 3: 46–60
Greene P, Kang U, Fahn S, Brin M, Moskowitz C, Flaster E (1990) Double-blind, placebo-controlled trial of botulinum toxin injections for the treatment of spasmodic torticollis. Neurology 40: 1213–1218
Grossman RG, Hamilton WJ (1993) Surgery for movement disorders. In: Jankovic J, Tolosa E (eds) Parkinson’s disease and movement disorders—2. Williams and Wilkins, Baltimore, pp 531–548
Guyton AC, McDonald MA (1947) Physiology of botulinus toxin. Arch Neurol Psychiatry 57: 578–592
Hallan RI, Williams NS, Melling J, Waldron DJ et al (1988) Treatment of anismus in intractable constipation with botulinum A toxin. Lancet 2: 714–717
Hambleton P (1992) Clostridium botulinum toxins: a general review of involvement in disease, structure, mode of action and preparation for clinical use. J Neurol 239: 16–20
Hambleton P, Cohen HE, Palmer BJ, Melling J (1992) Antitoxins and botulinum toxin treatment. BMJ 304: 959–960
Hatheway CH, Snyder JD, Seals JE, Edell TA, Lewis GE Jr et al (1984) Antitoxin levels in botulism patients treated with trivalent equine botulism antitoxin to toxin types A, B, and E. J Infect Dis 150: 407–412
Helveston EM, Pogrebiniak AE (1988) Treatment of acquired nystagmus with botulinum A toxin. Am J Opthalmol 106: 584–586
Herrero BA, Ecklung AE, Streett CS, Ford DF, King J K (1967) Experimental botulism in monkeys—a clinical pathological study. Exp Mol Pathol 6: 84–95
Huttner WB (1993) Snappy exocytotoxins. Nature 365: 104–105
Jahanshahi M, Marion M-H, Marsden CD (1990) Natural history of adult-onset idiopathic torticollis. Arch Neurol 47: 548–552
Janetta PJ, Abbasy M, Maroon JC, Ramos FM, Albin MS (1977) Etiology and definitive microsurgical treatment of hemifacial spasm. J Neurosurg 47: 321–328
Jankovic J (1988) Etiology and differential diagnosis of blepharospasm and oromandibular dystonia. Adv Neurol 49: 103–116
Jankovic J (1994a) Treatment of tics with botulinum toxin. In: Jankovic J, Hallet M (eds) Therapy with botulinum toxin. Dekker, New York, pp 503–510
Jankovic J (1994b) Botulinum toxin in the treatment of dystonic tics. Mov Disord 9: 347–349
Jankovic J, Brin MF (1991) Therapeutic uses of botulinum toxin. N Engl J Med 324: 1186–1194
Jankovic J, Fahn S (1993) Dystonic syndromes. In: Jankovic J, Tolosa E (eds) Parkinson’s disease and movement disorders—2. Williams and Wilkins, Baltimore, pp 337–374
Jankovic J, Hallett M (eds) (1994) Therapy with botulinum toxin. Dekker, New York
Jankovic J, Orman J (1987) Botulinum A toxin for cranial-cervical dystonia: a double-blind, placebo-controlled study. Neurology 37: 616–623
Jankovic J, Schwartz K (1990) Botulinum toxin injections for cervical dystonia. Neurology 40: 277–280
Jankovic J, Schwartz K (1991a) Clinical correlates of response to botulinum toxin injections. Arch Neurol 48: 1253–1256
Jankovic J, Schwartz K (1991b) Botulinum toxin treatment of tremors. Neurology 41: 1185–1188
Jankovic J, Schwartz K (1993a) Longitudinal follow-up of botulinum toxin injections for treatment of blepharospasm and cervical dystonia. Neurology 43: 834–836
Jankovic J, Schwartz K (1993b) The use of botulinum toxin in the treatment of hand dystonias. J Hand Surg 18A: 883–887
Jankovic J, Shale H (1989) Dystonia in musicians. Semin Neurol 9: 131–135
Jankovic J, Friedman D, Pirozzolo FJ, McCrary JA (1990a) Progressive supranuclear palsy: motor, neurobehavioral, and neuro-opthalmic findings. Adv Neurol 53: 293–304
Jankovic J, Schwartz K, Donovan D (1990b) Botulinum toxin treatment of cranial-cervical dystonia, spasmodic dysphonia, other focal dystonias and hemifacial spasms. J Neurol Neurosurg Psychiatry 53: 633–639
Jankovic J, Leder S, Warner D, Schwartz K (1991) Cervical dystonia: clinical findings and associated movement disorders. Neurology 41: 1088–1091
Jayne D, Lees AJ, Stern GM (1984) Remission in spasmodic torticollis. J Neurol Neurosurg Psychiatry 47: 1236–1237
Jordan DR, Anderson RL, Thiese SM (1989) Intractable orbicularis myokymia: treatment alternatives. Ophthalmic Surg 20: 280–283
Kao I, Drachman DB, Price DL (1976) Botulinum toxin: mechanism of presynaptic blockade. Science 193: 1256–1258
Karp BI, Cole RA, Cohen LG et al (1994) Long-term botulinum toxin treatment of focal hand dystonia. Neurology 44: 70–76
Katz B, Rosenberg JH (1987) Botulinum therapy for apraxia of eyelid opening. Am J Ophthalmol 103: 718–719
Koay CE, Alun-Jones T (1989) Pharyngeal paralysis due to botulinum toxin. J Laryngol Otol 103: 698–699
Kraft SP, Lang AE (1988) Botulinum toxin injections in the treatment of blepharospasm, hemifacial spasm, and eyelid fasciculations. Can J Neurol Sci 15: 276–280
Lange DJ, Brin MF, Warner CL, Fahn S, Lovelace RE (1987) Distant effects of local injection of botulinum toxin. Muscle Nerve 10: 552–555
Lees AJ, Turjanski N, Rivest J, Whurr R, Lorch M, Brookes G (1992) Treatment of cervical dystonia, hand spasms, and laryngeal dystonia with botulinum toxin. J Neurol 239: 1–4
Lorentz IT, Subramanian SS, Yiannikas C (1991) Treatment of idiopathic spasmodic torticollis with botulinum toxin A: a double-blind study on twenty-three patients. Mov Disord 6: 145–150
Ludlow CL (1990) Treatment of speech and voice disorders with botulinum toxin. JAMA 264: 2671–2675
Ludlow CL, Naunton RF, Sedory SE, Schulz GM, Hallett M (1988) Effects of botulinum toxin injections on speech in adductor spasmodic dysphonia. Neurology 38: 1220–1225
Ludlow CL, Sedory SE, Fujita M, Naunton RF (1989) Treatment of voice tremor with botulinum toxin injection. Neurology 39 [Suppl 1]: 353
Ludlow CL, Naunton RF, Jujita M, Sedory SE (1990) Spasmodic dysphonia: botulinum injection after recurrent nerve surgery. Otolaryngol Head Neck Surg 102: 122–131
Ludlow CL, Hallett M, Rhew K, Cole R, Shimizu T, Sakaguchi G, Bagley JA, Schulz GM, Yim SG, Koda S (1992) Therapeutic use of type F botulinum toxin. N Engl J Med 326: 349–350
Magoon EH (1984) Botulinum toxin chemo-denervation for strabismus in infants and children. J Pediatr Ophthalmol Strabismus 21: 110–113
Magoon EH (1989) Chemodenervation of strabismic children: a 2-to 5-year follow-up study compared with shorter follow-up. Ophthalmology 96: 931–934
Magoon EH, Dakoske C (1985) Botulinum toxin injection for vertical strabismus. Am Orthop J 35: 48–52
Marsden CD, Sheehy MP (1990) Writer’s cramp. Trends Neurosci 13: 148–153
Mauriello JA (1985) Blepharospasm, Meige syndrome, and hemifacial spasm: treatment with botulinum toxin. Neurology 35: 1499–1500
Mauriello JA Jr, Coniaris H, Haupt EJ (1987) Use of botulinum toxin in the treatment of one hundred patients with facial dyskinesias. Ophthalmology 94: 976–979
Melling J, Hambleton P, Shone CC (1988) Clostridium botulinum toxins: nature and preparation for clinical use. Eye 2: 16–23
Miller RH, Woodson GE, Jankovic J (1987) Botulinum toxin injection of the vocal fold for spasmodic dysphonia. A preliminary report. Arch Otolaryngol Head Neck Surg 113: 603–605
National Institutes of Health Consensus Development Conference (1991) Statement on Clinical Use of Botulinum Toxin. Arch Neurol 48: 1294–1298
Newman NJ, Lambert SR (1992) Botulinum toxin treatment of supranuclear ocular motility disorders. Neurology 42: 1391–1393
Olney RK, Aminoff MJ, Gelb DJ, Lowenstein DH (1988) Neuromuscular effects distant from the site of botulinum neurotoxin injection. Neurology 38: 1780–1783
Ozelius L, Kramer PL, Moskowitz CB, Kwiatkowski DJ, Brin MF, Bressman SB, Schuback DE, Falk CT, Risen M, de Leom D, et al. (1989) Human gene for torsion dystonia located on chromosome 9q 32–34. Neuron 2: 1427–1434
Ozelius LJ, Kramer PL, de Leon D, Risch N, Bressman SB, Schuback DE, Brin MF, Kwiatkowski DJ, Burke RE, Gusella JF et al. (1992) Strong allelic association between the torsion dystonia gene (DYT1) and loci in chromosome 9q34 in Ashkenazi Jews. Am J Hum Genet 50: 619–628
Pamphlett R (1989) Early terminal and nodal sprouting of motor axons after botulinum toxin. J Neurol Sci 92: 181–192
Pasricha PJ, Kaloo AN (1994) Botulinum toxin in the treatment of gastrointestinal disorders. In: Jankovic J, Hallet M (eds) Therapy with botulinum toxin. Dekker, New York, pp 543–556
Pestronk A, Drachman DB (1978) Motor nerve sprouting and acetylcholine receptors. Science 199: 1223–1225
Pestronk A, Drachman DB, Griffin JW (1976) Effect of botulinum toxin on trophic regulation of acetylcholine receptors. Nature 264: 787–789
Poewe W, Schelosky L, Kleedorfer B, Heimen F, Wagner M, Deuschl G et al. (1992) Treatment of spasmodic torticollis with local injections of botulinum toxin. One-year follow-up in 37 patients. J Neurol 239: 21–25
Poewe W, Wissel J (1994) Experience with botulinum toxin in cervical dystonia. In: Jankovic J, Hallet M (eds) Therapy with botulinum toxin. Dekker, New York, pp 267–278
Polo KB, Jabberi B (1994) Effectiveness of botulinum toxin type A against painful limb myoclonus of spinal cord origin. Mov Disord 9: 233–235
Pool KD, Freeman FJ, Finitzo T, Hayashi MM, Chapman SB, Devous MD, Close LG Jr, Kondrasue GV, Memdelsohn D, Schaefer SB et al. (1991) Heterogeneity in spasmodic dysphonia. Neurologic and voice findings. Arch Neurol 48: 305–309
Putterman AM (1990) Botulinum toxin injections in the treatment of seventh nerve misdirection. Am J Ophthalmol 110: 205
Quinn N, Hallett M (1989) Dose standardization of botulinum toxin. Lancet 1: 964
Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology (1990) Assessment: the clinical usefulness of botulinum toxin-A in treating neurologic disorders. Neurology 40: 1332–1336
Rhoad RCM, Stern PJ (1993) Writer’s cramp—a focal dystonia: etiology, diagnosis, and treatment. J Hand Surg 18A: 542–544
Rivest J, Lees AJ, Marsden CD (1991) Writer’s cramp: treatment with botulinum toxin injection. Mov Disord 6: 55–59
Rondot P, Marchand MP, Dellatolas G (1991) Spasmodic torticollis—review of 220 patients. Can J Neurol Sci 18: 143–151
Rosenbaum F, Jankovic J (1988) Focal task-specific tremor and dystonia: categorization of occupational movement disorders. Neurology 38: 522–527
Rosenbaum AL, Kushner BJ, Kirschen D (1989) Vertical rectus muscle transposition and botulinum toxin (Oculinum) to medial rectus for abducens palsy. Arch Opthalmol 107: 820–823
Sachdev P (1992) Golfers’ cramp: clinical characteristics and evidence against it being an anxiety disorder. Mov Disord 7: 326–332
Sakaguchi G (1983) Clostridium botulinum toxins. Pharmacol Ther 19: 165–194
Sanders DB, Massey EW, Buckley EG (1986) Botulinum toxin for blepharospasm: single-fiber EMG studies. Neurology 36: 545–547
Schantz EJ, Johnson EA (1990) Dose standardization of botulinum toxin. Lancet 335: 421
Schantz EJ, Johnson EA (1992) Properties and use of botulinum toxin and other microbial neurotoxins in medicine. Microb Rev 56: 80–99
Schiavo G, Benfenati F, Poulain B et al (1992) Tetanus and botulinum-B neurotoxins block neurotransmitter release by proteolytic of synaptobrevin. Nature 359: 3577–3583
Schiavo G, Shone CC, Rossetto O, Alexandre FCG, Montecucco C (1993a) Botulinum neurotoxin serotype F is a zinc endopeptidase specific for VAMP/synaptobrevin. J Biol Chem 268: 11516–11519
Schiavo G, Rossetto O, Catsicas S, Polverino de Laureto P, DasGupta BR, Benfenati F, Montecucco C (1993b) Identification of the nerve-terminal targets of botulinum neurotoxins serotypes A, D and E. J Biol Chem 268: 23784–23787
Schiavo G, Santucci A, DasGupta BR, Metha PP, Jontes J, Benfenati F, Wilson MC, Montecucco C (1993c) Botulinum neurotoxins serotypes A and E cleave SNAP-25 at distinct COOH-terminal peptide bonds. FEBS Lett 335, 99–103
Schiavo G, Malizio C, Trimble WS, Polverino de Laureto P, Milan G, Sugiyama H, Johnson EA, Montecucco C (1994). Botulinum G neurotoxin cleaves VAMP/synaptobrevin at a single Ala/Ala peptide bond. J Biol Chem 269 (in press)
Scott AB (1980) Botulinum toxin injection into extraocular muscles as an alternative to strabismus surgery. Ophthalmology 87: 1044–1049
Scott AB (1981) Botulinum toxin injection of eye muscles to correct strabismus. Trans Am Opthalmol Soc 79: 734–770
Scott AB, Kraft SP (1985) Botulinum toxin in injection in the management of lateral rectus paresis. Opthalmology 92: 676–683
Scott AB, Suzuki D (1988) Systemic toxicity of botulinum toxin by intramuscular injection in the monkey. Mov Disord 3: 333–335
Scott AB, Rosenbaum A, Collins CC (1973) Pharmacologic weakening of extraocular muscles. Invest Ophthalmol 12: 924–927
Scott AB, Kennedy RA, Stubbs HA (1985) Botulinum A toxin injection as a treatment for blepharospasm. Arch Opthalmol 103: 347–350
Scott AB, Magoon EH, McNeer KW, Stager DR (1990) Botulinum treatment of strabismus in children. Trans Am Opthalmol Soc 87: 174–180
Sellin LC (1981) The action of botulinum toxin at the neuromuscular junction. Med Biol 59: 10–11
Shone CC, Hambleton P, Melling J (1987) A 50 kDa fragment from the NH2 terminus of the heavy subunit of Clostridium botulinum type A neurotoxin forms channels in lipid vesicles. Eur J Biochem 167: 175–180
Simpson LL (1981) The origin, structure, and pharmacologic activity of botulinum toxin. Pharmacol Rev 33: 155–188
Simpson LL (1989) Peripheral actions of the botulinum toxins. In: Simpson LL (ed) Botulinum neurotoxin and tetanus toxin. Academic. San Diego pp 153–178
Sketelj J, Örne-Finderle N, Sket D, Dettbarn WD, Brzin M (1993) Comparison between the effects of botulinum toxin-induced paralysis and denervation on molecular forms of acetylcholinesterase in muscles. J Neurochem 61: 501–508
Snow BJ, Tsui JKC, Bhatt MH, Varelas M, Hashimoto SA, Calne DB (1990) Treatment of spasticity with botulinum toxin: a double-blind study. Ann Neurol 28: 512–515
Söllner T, Whiteheart SW, Brunner M et al (1993) SNAP receptors implicated in vesicle targeting and fusion. Nature 362: 318–324
Stacy M, Cardoso F, Jankovic J (1993) Tardive stereotypy and other movement disorders in tardive dyskinesias. Neurology 43: 937–941
Stanley EF, Drachman DB (1983) Botulinum toxin blocks quantal but not non-quantal release of ACh at the neuromuscular junction. Brain Res 261: 172–175
Talbot JF, Gregor Z, Bird AC (1982) The surgical management of essential blepharoespasm. In: Marsden CD, Fahn S (eds) Movement disorders. Butterworth, London, pp 322–329
Tolosa E, Marti MJ, Kulisevsky J (1988) Botulinum toxin injection therapy for hemifacial spasm. Adv Neurol 49: 479–491
Trosch RM, Pullman SL (1994) Botulinum Toxin A Injections for the treatment of hand tremors. Mov Disord 9: 601–609
Tse CK, Dolly JO, Hambleton P, Wray D, Melling J (1982) Preparation and characterization of homogeneous neurotoxin type A from Clostridium botulinum. Eur J Biochem 122: 493–500
Tsui JKC, O’Brien C (1994) Clinical trials for spasticity. In: Jankovic J, Hallet M (eds) Therapy with botulinum toxin. Dekker, New York, 523–534
Tsui JK, Eisen A, Stoessl AJ, Calne S, Calne DB (1986) Double-blind study of botulinum toxin in spasmodic torticollis. Lancet 2: 245–247
Tsui JK, Eastmann M, Mak E, Calne S, Calne DB (1987a) Botulinum toxin in writer’s cramp: a pilot study. Ann Neurol 22: 147
Tsui JKC, Fross RD, Calne S, Calne DB (1987b) Local treatment of spasmodic torticollis with botulinum toxin. Can J Neurol Sci 14: 533–535
Tsui JK, Wong NLM, Wong E, Calne DB (1988) Production of circulating antibodies to botulinum-A toxin in patients receiving repeated injections for dystonia. Ann Neurol 23: 181
Tsui JK, Snow B, Bratt M et al. (1990) New applications of botulinum toxin in the lower limbs. Neurology 40(Supp 1): 382
Tsui JKC, Bhatt M, Calne S, Calne DB (1993) Botulinum toxin in the treatment of writer’s cramp: a double-blind study. Neurology 43: 183–185
van Ermengem E (1897) Über einen neuen anaeroben Bacillus und seine Beziehungen zum Botulismus. Z Hyg Infektionskrankh 26: 1–56 [English translation, Rev Infect Dis 1: 701–719]
Waddy HM, Fletcher NA, Harding AE, Marsden CD (1991) A genetic study of idiopathic focal dystonias. Ann Neurol 29: 320–324
Whurr R, Lorch M, Fontana H, Brookes G, Lees A, Marsden CD (1993) The use of botulinum toxin in the treatment of adductor spasmodic dysphonia. J Neurol Neurosurg Psychiatry 56: 526–530
Wiegand H, Wellhoner HH (1977) The action of botulinum A neurotoxin on the inhibition by antidromic stimulation of the lumbar monosynaptic reflex. Naunyn Schmied Arch Pharmacol 298: 235–238
Wiegand H, Erdmann G, Wellhoner HH (1976) 125l-Labelled botulinum A neurotoxin: pharmacokinetics in cats after neuromuscular injection. Naunyn Schmiedebergs Arch Pharmacol 292: 161–165
Yamasaki S, Binz T, Hayashi T, Szabo E, Yamasaki N, Eklund M, Jahn R, Niemann H (1994) Botulinum neurotoxin type G proteolyses the Ala81 Ala82 bond of rat synaptobrevin 2. Biochem Biophys Res Commun 200: 829–835
Zuber M, Sebald M, Bathien N, de Recondo J, Rondot P (1993) Botulinum antibodies in dystonic patients treated with type A botulinum toxin: frequency and significance. Neurology 43: 1715–1718
Zwirner P, Murry T, Swenson M, Woodson GE (1991) Acoustic changes in spasmodic dysphonia after botulinum toxin injection. J of Voice 5: 1: 78–84
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1995 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Cardoso, F., Jankovic, J. (1995). Clinical Use of Botulinum Neurotoxins. In: Montecucco, C. (eds) Clostridial Neurotoxins. Current Topics in Microbiology and Immunology, vol 195. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-85173-5_6
Download citation
DOI: https://doi.org/10.1007/978-3-642-85173-5_6
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-85175-9
Online ISBN: 978-3-642-85173-5
eBook Packages: Springer Book Archive